Safety and Clinical Efficacy Evaluation of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer
The goal of this clinical trial is to verify the safety and clinical benefit of pulsed electric field(PEF) treatment of metastatic non-small cell lung cancer(NSCLC) patients with acquired resistance to anti programmed cell death protein 1(PD-1) monoclonal antibody therapy. The main questions it aims to answer are: * Safety of PEF treatment of metastatic NSCLC patients. * Control of ablated and other targeted lesions. * Local and peripheral immunoregulation effect. PEF energy will be delivered to preselected lesions of participants, then anti PD-1 will be routinely administrated if no adverse event(AE)/serious adverse event(SAE) which need medical intervention occurs.
• Patients over 22 years old with pathologically confirmed non-small cell lung cancer stage III-IV.
• Patients received first-line anti PD-1 immunotherapy and had disease progression.
• Lesions to be ablated must be ≤ 3cm in longest diameter(LD).
• \* The leison to be ablated can be ≤ 5cm in LD, if evaluated as possible with multiple energy delivery in a single session.
• More than one measurable lesion according to RECIST 1.1 except PEF targeted lesions.
• Eastern Cooperative Oncology Group(ECOG) performance status 0-1
• Life expectancy ≥3 months
• Fully understand the treatment plan and sign the informed consent form voluntarily.